CAS: 198348-89-9; 5-Nitro-3-Pyrazolecarboxylic Acid

该化合物是一种有机化合物,其特点是其配有五人环状结构,内含两个相邻氮原子的五人环;一个硝基化合物组(-NO2)存在于5号位置,一个箱状酸组(-COOH)存在于3号位置,有助于其化学反应和潜在应用;该化合物一般在室温下是固体,由于碳本体酸功能,极地溶剂中可能出现中等溶解性;其硝基化合物组可参与电极替代反应,而碳本体酸组可参与酸基反应;该化合物还可显示生物活动,使其对药物研究感兴趣;此外,其独特结构允许其他复杂分子合成的潜在用途;应参考安全数据处理处理,因为硝基化合物敏感,需要适当的防范.

结构式图片

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

  • 1453-58-3 = 198348-89-9
    反应条件:1.1
    标题:Synthesis Of Novel Azides And Triazoles On The Basis Of 1H-Pyrazole-3(5)-Carboxylic Acids
    作者:By Dalinger,Aleksander I. Et Al
    参考文献:Chemistry Of Heterocyclic Compounds (New York 日期:2020 卷标:56(2) 页码:180-191]

    39846-84-9 = 198348-89-9
    反应条件:1.1R:Naoh
    标题:3-Substituted Pyrazoles And 4-Substituted Triazoles As Inhibitors Of Human 15-Lipoxygenase-1
    作者:By Pelcman,Benjamin Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2015 卷标:25(15) 页码:3024-3029]

    34334-96-8 = 198348-89-9
    反应条件:1.1R:H2So4,R:Na2Cr2O7,S:H2O,60-65°C; 8 H,60-65°C
    标题:Nitropyrazoles 18. Synthesis And Transformations Of 5-Amino-3,4-Dinitropyrazole
    作者:By Dalinger,I. L. Et Al
    参考文献:Russian Chemical Bulletin 日期:2010 卷标:59(8) 页码:1631-1638]

    1453-58-3 = 198348-89-9
    反应条件:1.1R:Hno3,R:Ac2O,S:Acoh,2 H,0-5°C1.2S:Cl2C=ccl2,8 H,Reflux2.1R:HCL,R:Na2Cr2O7,S:H2O,10 H,65-70°C
    标题:Liquid-Phase Synthesis Of Combinatorial Libraries Based On 7-Trifluoromethyl-Substituted Pyrazolo[1,5-A]Pyrimidine Scaffold
    作者:By Dalinger,Igor L. Et Al
    参考文献:Journal Of Combinatorial Chemistry 日期:2005 卷标:7(2) 页码:236-245

海关参考信息

专利信息


专利号:US-2005239808-A1
优先权日:2002-05-10
标题 :Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
发明人:SCHRADER THOMAS; RIESNER DETLEV; RZEPECKI PETRA; NAGEL-STEGER LUITGARD; WEHNER MARK; KIRSTEN CHRISTIAN; MOLT OLIVER; ZADMARD REZA; ASCHERMANN KATJA
权利人:SCHRADER THOMAS; RIESNER DETLEV; RZEPECKI PETRA; NAGEL-STEGER LUITGARD; WEHNER MARK; KIRSTEN CHRISTIAN; MOLT OLIVER; ZADMARD REZA; ASCHERMANN KATJA
摘要:The invention on hand refers to diseases associated with abnormal protein structures, including Alzheimer's disease, Creutzfeldt-Jakob's disease, BSE and other prion-associated diseases. It is the task of the invention on hand to provide new active agents preventing the formation of amyloid plaques and to dissolve existing plaques, such agents being convenient for therapy, diagnosis and prophylaxis of diseases that are associated with abnormal protein structures. This task is performed in terms of the current invention by heterocyclic or aromatic agents with a rigid structure and a donor-acceptor-donor pattern (DAD), the latter being formed by donors and acceptors of hydrogen bridge linkages which comply with the β-sheet structure of the peptide or protein and thus fit as binding partners. The heterocyclic or aromatic agents are available at least as dimers. They recognise peptides and proteins with a β-sheet structure, form stable complexes with them and inhibit their aggregation to β-amyloid plaques. Furthermore, the new active agents are able to dissolve β-amyloid plaques that already exist. Another task of the current invention is to provide methods for the synthesis of said heterocyclic or aromatic compounds.

专利号:US-2024400552-A1
优先权日:2016-11-11
标题 :Heterocyclic modulators of lipid synthesis
发明人:BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-11622968-B2
优先权日:2011-03-08
标 题:Heterocyclic modulators of lipid synthesis
发明人:BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-10226449-B2
优先权日:2013-12-20
标 题:Heterocyclic modulators of lipid synthesis and combinations thereof
发明人:HEUER TIMOTHY SEAN; OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREGORY; OHOL-GUPTA YAMINI; O'FARRELL MARIE
权利人:3 V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

专利号:US-11034690-B2
优先权日:2016-11-11
标 题:Heterocyclic modulators of lipid synthesis
发明人:BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC; SAGINIET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-9428502-B2
优先权日:2012-07-03
标题:Heterocyclic modulators of lipid synthesis
发明人:OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; WAGMAN ALLAN S
权利人:3-V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1016/j.bmcl.2012.07.091
摘要:Leurs U, Clausen RP, Kristensen JL, Lohse B. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C). Bioorganic & Medicinal Chemistry Letters. 2012 Sep;22(18):5811–3. doi: 10.1016/j.bmcl.2012.07.091.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知